September 19, 2022
Angiex submits IND to FDA for AGX101
CAMBRIDGE, Mass. — September 19, 2022: Angiex, developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for…
September 29, 2022
Angiex Further Bolsters its Executive Team with the Appointment of Jason Sager, MD, as Chief Medical Officer
Dr. Sager joins after 18 months as part-time CMO, in which he built the clinical…